This is the peptide area with the strongest human evidence — but that evidence is concentrated in the approved GLP-1 drugs, which are prescription medications with real side-effect profiles and belong under medical supervision. The investigational and research compounds below are studied for related mechanisms, not proven weight-loss treatments.
Peptides researched for this goal
A GLP-1 receptor agonist approved for type 2 diabetes and weight management.
A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management.
An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss.
A long-acting amylin analog studied for appetite and weight, often with semaglutide.
An investigational GLP-1/glucagon dual agonist studied for weight and liver health.
A mitochondrial-derived peptide studied for metabolism and exercise.
Frequently asked questions
Semaglutide and Tirzepatide have the strongest evidence and are FDA-approved for weight management, but "best" depends on the individual and is a decision for a clinician. Selpho does not prescribe or provide dosing.
The approved GLP-1 medications have known side effects (commonly gastrointestinal) and require medical supervision. Investigational compounds are not established as safe or effective for weight loss.
Get a stack matched to your goals
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.